Interleukin-17 and Kidney Allograft Outcome

• Published in: Transplantation proceedings Vol. 41; no. 5; pp. 1562 - 1564
• Main Authors: Crispim, J.C.O, Grespan, R, Martelli-Palomino, G, Rassi, D.M, Costa, R.S, Saber, L.T, Cunha, F.Q, Donadi, E.A
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Inc 01.06.2009; Elsevier
• Subjects: Adult; Animals; Biological and medical sciences; Biomarkers - blood; Biopsy; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Graft Rejection - blood; Graft Rejection - immunology; Humans; Immunosuppressive Agents - therapeutic use; Interleukin-17 - blood; Male; Medical sciences; Mice; Middle Aged; Reference Values; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tissue, organ and graft immunology; Medicine; Prognosis; Treatment; Urinary system; Surgery; Evolution; Graft; Transplantation; Homotransplantation; Interleukin 17; Kidney
• DOI: 10.1016/j.transproceed.2009.01.092
• ISSN: 0041-1345

Abstract Acute rejection episodes (ARE) are important complications that involve the interplay between mechanisms that maintain graft tolerance and promote rejection. The proinflammatory cytokine interleukin-17 (IL-17) has been implicated in many conditions in humans and mice. In kidney transplant patients, the evaluation IL-17 levels has been performed in only a few patients. We performed a cross-sectional study correlating quantitative IL-17 levels and clinical outcomes. Patients and methods We studied 19 specimens from biopsies performed in patients ( n = 19) who received isolated kidney grafts. ARE signs were present in 9 (47%) patients who provide specimens; whereas, 10 (53%) others showed no signs of rejection. Eighteen healthy control sample IL-17 underwent measurement, all of which were performed by an enzyme-linked immunosorbent assay method. We assessed other factors, such as the recipients demographic data, cold ischemia time, HLA mismatches, time elapsed from transplantation to the biopsy, posttransplantation status, antibody panel, donor type, and immunosuppressive treatment. Results IL-17 levels were clearly increased among samples derived from patients with ongoing rejection (125.7 ± 27.06 pg/mL) in contrast, to the nonrejection group, (30 ± 13.32 pg/mL) ( P < .05). Healthy controls showed no detectable IL-17 levels. Conclusions These findings suggested that IL-17 was important in the pathophysiology of acute kidney rejection.